177 related articles for article (PubMed ID: 32737860)
1. A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs.
De Benedetto I; Trunfio M; Guastamacchia G; Bonora S; Calcagno A
J Neurovirol; 2020 Oct; 26(5):642-651. PubMed ID: 32737860
[TBL] [Abstract][Full Text] [Related]
2. Lifetime antiretroviral exposure and neurocognitive impairment in HIV.
Amusan P; Power C; Gill MJ; Gomez D; Johnson E; Rubin LH; Fujiwara E
J Neurovirol; 2020 Oct; 26(5):743-753. PubMed ID: 32720232
[TBL] [Abstract][Full Text] [Related]
3. Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir.
Keegan MR; Winston A; Higgs C; Fuchs D; Boasso A; Nelson M
J Neurovirol; 2019 Feb; 25(1):85-90. PubMed ID: 30478800
[TBL] [Abstract][Full Text] [Related]
4. Efavirenz-Associated Retinal Toxicity Presenting with Night Vision Defects in Patients with Human Immunodeficiency Virus.
Sudharshan S; Kumar KD; Bhende M; Biswas J; Selvamuthu P
Ocul Immunol Inflamm; 2020 Oct; 28(7):1076-1084. PubMed ID: 32870052
[TBL] [Abstract][Full Text] [Related]
5. Perinatal exposure of rats to the HIV drug efavirenz affects medial prefrontal cortex cytoarchitecture.
Garcia LP; Van de Wijer L; Hanswijk SI; Rando J; Witteveen JS; Middelman A; Ter Heine R; de Mast Q; Martens GJM; van der Ven AJAM; Schellekens AFA; Homberg JR; Kolk SM
Biochem Pharmacol; 2020 Aug; 178():114050. PubMed ID: 32446887
[TBL] [Abstract][Full Text] [Related]
6. Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz.
Blas-García A; Polo M; Alegre F; Funes HA; Martínez E; Apostolova N; Esplugues JV
J Antimicrob Chemother; 2014 Nov; 69(11):2995-3000. PubMed ID: 25011651
[TBL] [Abstract][Full Text] [Related]
7. Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?
Winston A; Pozniak A; Smith N; Fletcher C; Mandalia S; Parmar D; Gibbons S; Back D; Gazzard B; Nelson M
AIDS; 2004 Feb; 18(3):572-4. PubMed ID: 15090815
[TBL] [Abstract][Full Text] [Related]
8. Maximizing Knowledge Extraction From Patient-Reported Outcome Data Using Exposure-Outcome Item Response Modeling Approach: Understanding Efavirenz-Induced Central Nervous System Toxicity.
Bisaso KS; Bisaso KR; Mukonzo JK; Ette EI
J Clin Pharmacol; 2020 Jun; 60(6):711-721. PubMed ID: 32096561
[TBL] [Abstract][Full Text] [Related]
9. Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation.
Pinillos F; Dandara C; Swart M; Strehlau R; Kuhn L; Patel F; Coovadia A; Abrams E
BMC Infect Dis; 2016 Feb; 16():56. PubMed ID: 26831894
[TBL] [Abstract][Full Text] [Related]
10. Neuroinflammation and EIF2 Signaling Persist despite Antiretroviral Treatment in an hiPSC Tri-culture Model of HIV Infection.
Ryan SK; Gonzalez MV; Garifallou JP; Bennett FC; Williams KS; Sotuyo NP; Mironets E; Cook K; Hakonarson H; Anderson SA; Jordan-Sciutto KL
Stem Cell Reports; 2020 Apr; 14(4):703-716. PubMed ID: 32220329
[TBL] [Abstract][Full Text] [Related]
11. Changes in functional connectivity in people with HIV switching antiretroviral therapy.
Toniolo S; Cercignani M; Mora-Peris B; Underwood J; Alagaratnam J; Bozzali M; Boffito M; Nelson M; Winston A; Vera JH
J Neurovirol; 2020 Oct; 26(5):754-763. PubMed ID: 32500477
[TBL] [Abstract][Full Text] [Related]
12. Early Antiretroviral Therapy Is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA Populations.
Oliveira MF; Chaillon A; Nakazawa M; Vargas M; Letendre SL; Strain MC; Ellis RJ; Morris S; Little SJ; Smith DM; Gianella S
PLoS Pathog; 2017 Jan; 13(1):e1006112. PubMed ID: 28046096
[TBL] [Abstract][Full Text] [Related]
13. 'High' antiretroviral deintensification strategy and cellular HIV DNA levels.
Lanzafame M; Lattuada E; Vincenzi M; Vecchi M; Luise D; Diani E; Gibellini D
J Chemother; 2020 Feb; 32(1):49-51. PubMed ID: 31809663
[No Abstract] [Full Text] [Related]
14. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus.
Kramer-Hämmerle S; Rothenaigner I; Wolff H; Bell JE; Brack-Werner R
Virus Res; 2005 Aug; 111(2):194-213. PubMed ID: 15885841
[TBL] [Abstract][Full Text] [Related]
15. The toxicogenetics of antiretroviral therapy: the evil inside.
Gutierrez Mdel M; Mateo MG; Vidal F; Domingo P
Curr Med Chem; 2011; 18(2):209-19. PubMed ID: 21110805
[TBL] [Abstract][Full Text] [Related]
16. Anti-HIV drugs promote β-amyloid deposition and impair learning and memory in BALB/c mice.
Zulu SS; Abboussi O; Simola N; Mabandla MV; Daniels WMU
Acta Neuropsychiatr; 2020 Oct; 32(5):257-264. PubMed ID: 32378496
[TBL] [Abstract][Full Text] [Related]
17. Frontline Science: CXCR7 mediates CD14
Veenstra M; Williams DW; Calderon TM; Anastos K; Morgello S; Berman JW
J Leukoc Biol; 2017 Nov; 102(5):1173-1185. PubMed ID: 28754798
[TBL] [Abstract][Full Text] [Related]
18. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study.
Manfredi R; Calza L; Chiodo F
J Acquir Immune Defic Syndr; 2004 Apr; 35(5):492-502. PubMed ID: 15021314
[TBL] [Abstract][Full Text] [Related]
19. CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose.
Calcagno A; Barco A; Trunfio M; Bonora S
Curr HIV/AIDS Rep; 2018 Feb; 15(1):84-91. PubMed ID: 29363025
[TBL] [Abstract][Full Text] [Related]
20. In vitro and Ex vivo Neurotoxic Effects of Efavirenz are Greater than Those of Other Common Antiretrovirals.
Ciavatta VT; Bichler EK; Speigel IA; Elder CC; Teng SL; Tyor WR; García PS
Neurochem Res; 2017 Nov; 42(11):3220-3232. PubMed ID: 28770436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
